Intervention

Gadoteridol

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common conditions6

Lead sponsors shown3

Clinical trials

3 shown

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsNCT04373564 · 2021-03-24

RECRUITING

Novel Imaging Markers in SPMSNCT05357833 · 2022-06-01

COMPLETED

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple SclerosisNCT03396822 · 2018-09-24

COMPLETED

Common conditions

Multiple Sclerosis2 Cognitive Function1 Contrast Media1 Motor Function1 Multiple Sclerosis, Secondary Progressive1 Secondary Progressive Multiple Sclerosis1

Leading sponsors

Guerbet 1 University of Maryland, Baltimore 1 University of Utah 1

Trial status mix

COMPLETED2

RECRUITING1

Phase mix

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.